Preoperative Doxorubicin Intravesical Chemotherapy in Recurrent Superficial Bladder Cancer

2015 ◽  
pp. 190-196
Author(s):  
Y. Kubota ◽  
M. Hosaka
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Intravesical Chemotherapy

Results of Transurethral Resection Plus Adjuvant Intravesical Chemotherapy for Superficial Bladder Cancer

1998 ◽  
Vol 5 (6) ◽  
pp. 534-539 ◽  
Author(s):  
Masashi Nomi ◽  
Kazuo Gohji ◽  
Masayuki Okamoto ◽  
Atsushi Takenaka ◽  
Yoshiharu Ono ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transurethral Resection ◽  
Superficial Bladder Cancer ◽  
Intravesical Chemotherapy

Intravesical Chemotherapy in the Treatment of Superficial Bladder Cancer

2003 ◽  
pp. 183-223 ◽  
Author(s):  
Vincent G Bird ◽  
Mark S Soloway ◽  
Per-Uno Malmström
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Intravesical Chemotherapy

scholarly journals Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Tomonori Kato ◽  
Kazushi Nomura ◽  
Fukuo Kondo ◽  
Masami Wakisaka ◽  
Akira Komiya
Keyword(s):  
Bladder Cancer ◽  
Tumor Recurrence ◽  
Superficial Bladder Cancer ◽  
Transitional Cell ◽  
Japanese Patients ◽  
Intravesical Instillation ◽  
Intravesical Chemotherapy ◽  
Low Grade ◽  
Free Rate

The high incidence of tumor recurrence following transurethral resection (TUR) represents a major problem encountered in the management of bladder cancer. This study examined the efficacy of intravesical chemotherapy in superficial bladder cancer. We retrospectively analyzed 90 Japanese cases with low-grade superficial transitional cell carcinoma (stage T1, grades 1 and 2) who were rendered tumor-free by TURBT (TUR of bladder tumor) and who thereafter were treated with or without intravesical chemotherapy. Among them, instillation was terminated in 2 patients due to adverse effects (severe but reversible chemical cystitis). Remaining 88 patients were divided into 2 groups according to therapy: the TURBT-only group(n=46), defined as patients treated with TURBT alone, and the Instillation group(n=42), defined as patients treated with weekly intravesical instillation therapies using epirubicin plus Ara-C. Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (p=0.02, HR = 0.457). The 5-year recurrence-free rate was 58.5% for the Instillation group and 38.6% for the TURBT-only group. Our instillation schedule represents the most intensive regimen among previously reported therapies and resulted in a 54.3% decrease in incidence of tumor recurrence. We believe that the results of this study could provide useful information on management of bladder cancer.

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1991 ◽  
Vol 20 (1) ◽  
pp. 19-25 ◽  
Author(s):  
E. Rintala ◽  
K. Jauhiainen ◽  
O. Alfthan ◽  
E. Hansson ◽  
H. Juusela ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Mitomycin C ◽  
Superficial Bladder Cancer ◽  
Intravesical Chemotherapy ◽  
Bacillus Calmette Guerin

292: Combined Local Bladder Hyperthermia and Intravesical Chemotherapy for the Treatment of High Grade Superficial Bladder Cancer

2004 ◽  
Vol 171 (4S) ◽  
pp. 77-77
Author(s):  
Ofer N. Gofrit ◽  
Amos Shapiro ◽  
Dov Pode ◽  
Ami A. Sidi ◽  
Ofer Nativ ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Intravesical Chemotherapy ◽  
High Grade
Sign in / Sign up

Export Citation Format

Share Document